Endo Announces Divestiture of International Pharmaceuticals Business
Portfolio Pulse from
Endo, Inc. has announced the divestiture of its International Pharmaceuticals business to Knight Therapeutics Inc. for up to $99 million. The deal includes an upfront payment of $84 million and potential future payments of $15 million.
March 11, 2025 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Endo, Inc. is divesting its International Pharmaceuticals business to Knight Therapeutics for up to $99 million, which includes an upfront payment and potential milestone payments.
The divestiture allows Endo to streamline its operations and focus on core business areas. The immediate cash inflow of $84 million and potential future payments could strengthen its financial position, likely having a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100